241 related articles for article (PubMed ID: 15210503)
1. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection.
Greenough A; Alexander J; Burgess S; Bytham J; Chetcuti PA; Hagan J; Lenney W; Melville S; Shaw NJ; Boorman J; Coles S; Turner J; Pang F
Arch Dis Child; 2004 Jul; 89(7):673-8. PubMed ID: 15210503
[TBL] [Abstract][Full Text] [Related]
2. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants.
Greenough A; Alexander J; Boit P; Boorman J; Burgess S; Burke A; Chetcuti PA; Cliff I; Lenney W; Lytle T; Morgan C; Raiman C; Shaw NJ; Sylvester KP; Turner J
Thorax; 2009 Jun; 64(6):490-5. PubMed ID: 19213770
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.
Broughton S; Roberts A; Fox G; Pollina E; Zuckerman M; Chaudhry S; Greenough A
Thorax; 2005 Dec; 60(12):1039-44. PubMed ID: 16227330
[TBL] [Abstract][Full Text] [Related]
4. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
5. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
6. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
[TBL] [Abstract][Full Text] [Related]
7. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants.
Broughton S; Bhat R; Roberts A; Zuckerman M; Rafferty G; Greenough A
Arch Dis Child; 2006 Jan; 91(1):26-30. PubMed ID: 16188957
[TBL] [Abstract][Full Text] [Related]
8. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection.
Greenough A; Cox S; Alexander J; Lenney W; Turnbull F; Burgess S; Chetcuti PA; Shaw NJ; Woods A; Boorman J; Coles S; Turner J
Arch Dis Child; 2001 Dec; 85(6):463-8. PubMed ID: 11719328
[TBL] [Abstract][Full Text] [Related]
9. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
10. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
[TBL] [Abstract][Full Text] [Related]
11. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
13. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
McCormick J; Tubman R
Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
Paes B; Cole M; Latchman A; Pinelli J
Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
[TBL] [Abstract][Full Text] [Related]
15. Lung function in prematurely born infants after viral lower respiratory tract infections.
Broughton S; Sylvester KP; Fox G; Zuckerman M; Smith M; Milner AD; Rafferty GF; Greenough A
Pediatr Infect Dis J; 2007 Nov; 26(11):1019-24. PubMed ID: 17984809
[TBL] [Abstract][Full Text] [Related]
16. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.
Forbes ML; Hall CB; Jackson A; Masaquel AS; Mahadevia PJ
J Med Econ; 2010 Mar; 13(1):136-41. PubMed ID: 20128663
[TBL] [Abstract][Full Text] [Related]
17. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery.
Leidy NK; Margolis MK; Marcin JP; Flynn JA; Frankel LR; Johnson S; Langkamp D; Simoes EA
Pediatrics; 2005 Jun; 115(6):1536-46. PubMed ID: 15930214
[TBL] [Abstract][Full Text] [Related]
18. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
Boyce TG; Mellen BG; Mitchel EF; Wright PF; Griffin MR
J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
[TBL] [Abstract][Full Text] [Related]
19. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
20. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions.
Weisman L
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
